ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to overcome resistance mechanisms in cancer. Its lead product candidates include enozertinib (formerly ORIC-114), a brain-penetrant, orally bioavailable irreversible inhibitor targeting EGFR exon 20 and HER2 exon 20 insertion mutations, currently in Phase 1b studies. Another candidate is rinzimetostat (formerly ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, also in Phase 1b. The company has clinical trial collaborations with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor, and with Johnson & Johnson to evaluate ORIC-944 in combination with Erleada AR inhibitor. ORIC aims to address key resistance pathways that limit the effectiveness of existing cancer treatments.

ORIC Pharmaceuticals, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ORIC. Its shares are traded in United States Dollars (USD). The company is headquartered in South San Francisco, California, and operates primarily in the United States. As a US-based biopharmaceutical company listed on a major US exchange, its financial reporting and stock trading are conducted in USD, making it accessible to investors through standard US brokerage accounts.

ORIC Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing novel therapies to address cancer drug resistance. The biotechnology industry involves using biological processes and living organisms to develop treatments, and ORIC's work in targeting resistance mechanisms places it at the forefront of precision oncology. Its pipeline includes small molecule inhibitors designed to overcome specific genetic mutations that cause treatment resistance, aligning with the broader biotech trend toward personalized medicine.

ORIC Pharmaceuticals, Inc. is headquartered in South San Francisco, California, United States. The company primarily serves the US market, as indicated by its focus on clinical trials and collaborations with US-based pharmaceutical partners like Bayer and Johnson & Johnson. Its research and development activities are centered in the San Francisco Bay Area, a major hub for biotechnology innovation. While its therapies are intended for global cancer patients, the company's current operations and clinical trials are predominantly conducted in the United States, with potential for future international expansion as its pipeline advances.

ORIC Pharmaceuticals has two main clinical-stage product candidates. Enozertinib (formerly ORIC-114) is a brain-penetrant, orally bioavailable irreversible inhibitor that selectively targets epidermal growth factor receptor (EGFR) exon 20 insertion mutations and human epidermal growth factor receptor 2 (HER2) exon 20 insertion mutations with high potency. It is currently in Phase 1b studies for cancers driven by these mutations. Rinzimetostat (formerly ORIC-944) is an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) for prostate cancer, also in Phase 1b. The company is evaluating these candidates in combination with established therapies: ORIC-944 with Bayer's Nubeqa (darolutamide) and with Johnson & Johnson's Erleada (apalutamide), both AR inhibitors, to potentially overcome resistance in prostate cancer.